Biomedical Engineering Reference
In-Depth Information
275. Woodland C, Ito S, Koren G. 1998. A model for the prediction of digoxin-drug interactions
at the renal tubular cell level. Ther Drug Monit 20: 134-138.
276. Kodawara T, Masuda S, Wakasugi H, Uwai Y, Futami T, Saito H, Abe T, Inui KI. 2002.
Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone
in the liver. Pharm Res 19: 738-743.
277. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield
L. 2000. Atorvastatin coadministration may increase digoxin concentrations by inhibition
of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 40: 91-98.
278. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten
Bokkel Huinink WW, Schellens JH. 2001. Co-administration of GF120918 significantly
increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:
42-47.
279. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF.
1997. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin
Pharmacol Ther 62: 41-49.
280. Gupta SK, Bakran A, Johnson RW, Rowland M. 1989. Cyclosporin-erythromycin inter-
action in renal transplant patients. Br J Clin Pharmacol 27: 475-481.
281. Gupta SK, Bakran A, Johnson RW, Rowland M. 1988. Erythromycin enhances the ab-
sorption of cyclosporin. Br J Clin Pharmacol 25: 401-402.
282. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. 1999. Effects of rifampin on
tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39: 91-96.
283. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. 1999. Pharma-
cokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum
perforatum). Clin Pharmacol Ther 66: 338-345.
284. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y.
2002. Identification of 779 genetic variations in eight genes encoding members of the
ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet 47: 147-171.
285. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. 2001. Identification
of human multidrug resistance protein 1 (MRP1) mutations and characterization of a
G671V substitution. J Hum Genet 46: 656-663.
286. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. 2001. Polymorphism of the
ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.
Pharmacogenetics 11: 175-184.
287. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa
T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K. 2002. Effects of polymor-
phisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal
enterocytes of healthy Japanese subjects. Biol Pharm Bull 25: 1356-1359.
288. Perdu J, Germain DP. 2001. Identification of novel polymorphisms in the pM5 and MRP1
(ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseu-
doxanthoma elasticum. Hum Mutat 17: 74-75.
289. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP. 2002.
A naturally occurring mutation in MRP1 results in a selective decrease in organic anion
transport and in increased doxorubicin resistance. Pharmacogenetics 4: 321-330.
290. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. 1996. Transport
of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate
export pump. Cancer Res 56: 988-994.
Search WWH ::
Custom Search